MindWalk Holdings Corp.
HYFT · Pharmaceutical Preparations · EDGAR filings ↗
Grade
D45gen composite 40pct→62; net margin <-100%; net + operating loss
Notable findings
- Cash burnNegative free cash flow (-5.2M)
- Customer concentration~49% of revenue from one customer/distributor — 3% from 49
- Material weaknessWe may fail to remediate a material weakness that could affect our financial reporting
- Net lossNet loss (net margin -123.3%)
- Notable holderHeld by 2 notable fund(s): RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
55.3%
Net margin
-123.3%
Return on equity
-128.0%
Return on assets
-68.0%
Revenue growth (QoQ)
84.9%
Current ratio
2.1×
Free cash flow
-$5M
Tangible book value
$10M
Cash & investments
$8M
Cash runway
6q
Leadership & compensation
| Name | Role | Latest total comp |
|---|---|---|
| Dr. Ilse Roodink | Officer | $482K FY2025 |
| Dr. Jennifer L. Bath | Officer | $1M FY2025 |
| Kari Graber | Officer | $394K FY2025 |
| Kristin Taylor | Officer | $472K FY2025 |
| Barry Springer | Director | $62K FY2025 |
| Chris Buyse | Director | $83K FY2025 |
| Dirk Witters | Director | $95K FY2025 |
| Mitch Levine | Director | $78K FY2025 |
Officers & directors from SEC filings (Form 4 + DEF 14A proxy); compensation is the latest reported fiscal year.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2025-07-29 | 2025-04-30 | 0000950170-25-099392 ↗ |
| 20-F | 2024-07-29 | 2024-04-30 | 0000950170-24-087127 ↗ |
| 40-F | 2023-07-10 | 2023-04-30 | 0000950170-23-032388 ↗ |
| 40-F | 2022-07-29 | 2022-04-30 | 0001193125-22-205824 ↗ |
| 40-F | 2021-07-28 | 2021-04-30 | 0001564590-21-038477 ↗ |